Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.47 |
| ▸ | NOS1 | P29475 | 9/20 | 0.47 |
| ▸ | NOS3 | P29474 | 6/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2839191 | 0.96 | NOS2 (0.47) | NOS2NOS1NOS3CYP11B1CYP11B2 | |
| SCHEMBL2831969 | 0.94 | NOS2 (0.46) | NOS2NOS1NOS3CYP11B1CYP11B2 | |
| SCHEMBL2836266 | 0.94 | NOS2 (0.45) | NOS2NOS1NOS3CYP11B1CYP11B2 | |
| SCHEMBL2834646 | 0.93 | NOS2 (0.53) | NOS2NOS1NOS3CYP11B1CYP11B2 | |
| SCHEMBL2836568 | 0.93 | NOS2 (0.47) | NOS2NOS1NOS3CYP11B1CYP11B2 | |
| SCHEMBL5033919 | 0.91 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9KMT2A | |
| SCHEMBL4151507 | 0.90 | NOS2 (0.51) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL2831827 | 0.89 | NOS1 (0.46) | NOS2NOS1NOS3CYP11B1CYP11B2 | |
| SCHEMBL4134667 | 0.86 | NOS2 (0.49) | NOS2NOS1NOS3CYP2C9KMT2A | |
| SCHEMBL2832509 | 0.86 | NOS2 (0.49) | NOS2NOS1NOS3CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-08-26 | — | — | US | claimed |
| US-7709488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1670796-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-25 | — | — | EP | claimed |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG | 2008-01-24 | — | — | US | claimed |
| US-7279488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NYCOMED GMBH (DE) | 2007-10-09 | — | — | US | claimed |
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-12-28 | — | — | US | claimed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | claimed |
| US-7709488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1670796-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-7279488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NYCOMED GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.